ArticleAntimicrobial agents and chemotherapy2000
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.Clinical pharmacokinetics · 2005Trial
- Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.Antimicrobial agents and chemotherapy · 2003Trial
- A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- The Specific Binding and Promotion Effect of Azoles on Human Aldo-Keto Reductase 7A2.Metabolites · 2023Article
- Characterization of Streptomyces sp. LS462 with high productivity of echinomycin, a potent antituberculosis and synergistic antifungal antibiotic.Journal of industrial microbiology & biotechnology · 2021Article
- ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity againstAntimicrobial agents and chemotherapy · 2019Article
- Animal Models of Aspergillosis.Comparative medicine · 2018Review
- Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.The Journal of infectious diseases · 2017Article
- The Mechanistic Targets of Antifungal Agents: An Overview.Mini reviews in medicinal chemistry · 2016Review
- Posaconazole: An Update of Its Clinical Use.Pharmacy (Basel, Switzerland) · 2015Review
- Benzotriazole: An overview on its versatile biological behavior.European journal of medicinal chemistry · 2015Review
- Drug strategies targeting CYP51 in neglected tropical diseases.Chemical reviews · 2014Review
- Conazoles.Molecules (Basel, Switzerland) · 2010Review
- Pharmacokinetic/pharmacodynamic profile of posaconazole.Clinical pharmacokinetics · 2010Review
- Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.Antimicrobial agents and chemotherapy · 2008Article
- Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.Antimicrobial agents and chemotherapy · 2008Article
- Review
- Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Antimicrobial agents and chemotherapy · 2007Article
- Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.Antimicrobial agents and chemotherapy · 2006Article
- In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SCH 56592 (posaconazole), a new triazole antifungal agent, was tested in vitro, and its activity was compared to that of itraconazole against 39 Aspergillus strains and to that of fluconazole against 275 Candida and 9 Cryptococcus strains. The SCH 56592 MICs for Aspergillus ranged from </=0.002 to 0.5 microg/ml, and those of itraconazole ranged from </=0.008 to 1 microg/ml. The SCH 56592 MICs for Candida and Cryptococcus strains ranged from </=0. 004 to 16 microg/ml, and those of fluconazole ranged from </=0.062 to >64 microg/ml. SCH 56592 showed excellent activity against Aspergillus fumigatus and Aspergillus flavus in a pulmonary mouse infection model. When administered therapeutically, the 50% protective doses (PD(50)s) of SCH 56592 ranged from 3.6 to 29.9 mg/kg of body weight, while the PD(50)s of SCH 56592 administered prophylactically ranged from 0.9 to 9.0 mg/kg; itraconazole administered prophylactically was ineffective (PD(50)s, >75 mg/kg). SCH 56592 was also very efficacious against fluconazole-susceptible, -susceptible dose-dependent, or -resistant Candida albicans strains in immunocompetent or immunocompromised mouse models of systemic infection. The PD(50)s of SCH 56592 administered therapeutically ranged from 0.04 to 15.6 mg/kg, while the PD(50)s of SCH 56592 administered prophylactically ranged from 1.5 to 19.4 mg/kg. SCH 56592 has excellent potential for therapy against serious Aspergillus or Candida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.